34 results about "Viral envelope" patented technology

The invention discloses a broad-spectrum novel coronavirus-resistant double-target polypeptide and application thereof, and relates to the field of biological medicines. The polypeptide drug provided by the invention can more effectively and synergistically inhibit the infection process of the virus by simultaneously acting on two key targets of RBD and HR1 of the virus. On one hand, through targeting RBD, combination of viruses and host cells can be blocked, so that the phenomenon that the viruses are adsorbed on the surfaces of the host cells is blocked, and the adsorption process of the viruses is restrained; on the other hand, by targeting HR1, formation of virus 6-HB can be interfered, and the fusion process of a virus envelope and a host envelope is further inhibited. The polypeptide capable of simultaneously targeting the double targets RBD and HR1 of the novel coronavirus, particularly R1L25HR2, provided by the invention, can effectively inhibit SARS-CoV-2 and a mutant strain thereof, and has broad-spectrum activity for resisting the novel coronavirus.

To provide methods for treating viral infections including SARS-CoV-2, and to provide polymers for use in such treatments.SOLUTION: Provided are improved amphiphilic comb-type polymers with well-controlled molecular weights, structures, and end groups, and hydrophilic backbones with regularly arranged hydrophobic substituents. The polymers self-assemble in an aqueous environment to form core-corona nanoparticles that are capable of disrupting envelope proteins of a virus and can further encapsulate antiviral drugs or their prodrugs. Regularly arranged targeting groups can also mediate the attachment of the nanoparticles to an envelope of the virus.SELECTED DRAWING: Figure 2

The present invention provides a cryopreservation solution for Koi herpesvirus, as well as its preparation method and application, relating to the field of virus preservation technology. The solution comprises 2-8 w / v% hydroxyethyl starch, 3-5 w / v% sucrose, and 1-3 w / v% bovine serum albumin. The Koi herpesvirus has an activity of ≥90% after resuscitation, can withstand five freeze-thaw cycles, can be stably frozen at -20°C, and has a shelf life of up to two years. This solution solves the technical problems in the prior art, such as the need to store cryopreservation solutions at ultra-low temperatures, the risk of osmotic pressure imbalance and viral envelope rupture, and low activity after cryopreservation and resuscitation.

An extracellular vesicle. The surface of the extracellular vesicle comprises at least part of a viral envelope glycoprotein or a variant thereof; the at least part of the viral envelope glycoprotein or the variant thereof does not bind to a receptor or the binding to a receptor is inhibited; and the extracellular vesicle is difficult to infect a cell by binding to a glycoprotein receptor. When the extracellular vesicle is used for delivering a target protein, the targeting performance of the extracellular vesicle is significantly improved. When an extracellular vesicle membrane expresses a hydrophobic protein, the expression and purification of the hydrophobic protein are facilitated.

Provided is a viral vector having a lipid bilayer envelope, the lipid bilayer envelope comprising an antibody binding domain displayed outside the envelope, the antibody binding domain being cell type specific; a viral envelope protein exhibited outside the envelope, the viral envelope protein being capable of promoting infection of the same cell type; and a nucleic acid molecule comprising a promoter capable of being expressed in the same cell type. Methods of making the viral vectors and methods of modifying cells and treating diseases / conditions using the viral vectors are also provided.

Disclosed herein are compositions and methods for determining the structure of a membrane protein. An epitope from a membrane-proximal external region (MPER) from a viral envelope protein can be grafted on to a variety of diverse membrane proteins to allow for binding structurally characterized antibody fragments, which can aid structural studies.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

The present disclosure relates to a novel vaccine strategy against hepatitis B virus (HBV) infection, which is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The disclosure provides fusion proteins that target dendritic cells (DCs), the key antigen-presenting cells of the immune system, and deliver HBV-derived peptides to both the major histocompatibility complex (MHC) class I and II pathways, thereby inducing strong and specific humoral and cellular immune responses against the viral envelope and core antigens. The disclosure also provides methods of using the fusion proteins for the prevention or treatment of HBV infection and its complications. The inventors have demonstrated in a mouse model that the DC-targeting HBV vaccine candidates can elicit robust antibody and T cell responses, which are essential for the clearance of the virus and the protection from chronic infection.

A viral vector having a lipid bilayer envelope is provided, comprising a cell-type specific antibody-binding domain presented outside the envelope, a viral envelope protein presented outside the envelope capable of promoting infection of the same cell type, and a nucleic acid molecule containing a promoter expressible in the same cell type. Furthermore, a method for producing the viral vector and a method for modifying cells and treating diseases / conditions using this viral vector are also provided.

Provided herein are lipid particles containing a viral envelope attachment protein, such as derived from paramyxovirus or baboon endogenous virus (BaEV). In some embodiments, the lipid particles also contain a codisplay protein, such as a transduction adjuvant or an immune stimulating protein. Also provided are such lipid particles that are viral vectors, such as lentiviral vectors or lentiviral-like particles. Also provided are producer cells and compositions containing such lipid particles and methods of making and using the lipid particles.

The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and / or the cytokine-based T-cell activating transmembrane protein.

Provided are a targeting vector and a method for targeting same to a host cell. The vector comprises a first molecule that binds to an endocytosis receptor of the target cell and a second molecule that promotes the release of a substance carried by the targeting vector into a cytoplasm. When the targeting vector is a viral vector, the first molecule is not part of a viral envelope protein, and the second molecule promotes endosomal escape or lysosomal escape of the targeting vector. The first molecule is designed according to the endocytosis receptor of the cell to be targeted, different types of cells can be targeted, and after a reasonable mutation is carried out on the vector, infection of cells that do not need to be targeted can be avoided, thereby improving the accuracy of the vector.

The present invention discloses a broad-spectrum dual-target polypeptide against the new coronavirus and its application, relating to the field of biomedicine. The polypeptide drug provided by the present invention can more effectively and synergistically inhibit the infection process of the virus by acting on the two key targets of the virus, RBD and HR1, at the same time. On the one hand, by targeting RBD, the binding of the virus to the host cell can be blocked, thereby hindering the adsorption of the virus on the surface of the host cell and curbing its adsorption process; on the other hand, by targeting HR1, the formation of the virus 6-HB can be interfered with, further inhibiting the fusion process of the viral envelope and the host envelope. The polypeptide that can simultaneously target the dual targets of the new coronavirus RBD and HR1, especially R1L25HR2, provided by the present invention, can effectively inhibit SARS-CoV-2 and its mutants, and has a broad-spectrum activity against the new coronavirus.

Viral particles for activating and transducing immune cells in vitro or in vivo, as well as compositions and methods for using said viral particles are provided. The present disclosure is based, at least in part, on the discovery that viral particles can be produced such that a cell surface protein is expressed on the viral envelope to simultaneously prime and transduce immune cells. In particular, as demonstrated herein, viral particles expressing a TCR targeting molecule and a costimulatory molecule enhance cell activation in vivo and transduction of nucleotides encoding a polypeptide of interest as compared to viral particles expressing only the TCR targeting molecule.

The application discloses a CD7 and CD3 double-targeting fusion protein and application thereof. Specifically, the application discloses an isolated fusion protein, which comprises, from N-terminal to C-terminal, (a) an anti-CD7 single-domain antibody (CD7 VHH); (b) an anti-CD3 single-domain antibody (CD3 VHH); and (c) a transmembrane region, which is used for anchoring the fusion protein on a cell membrane or a viral envelope. And a T cell-targeting pseudotyped lentiviral vector based on the fusion protein is constructed. The pseudotyped lentiviral vector of the application can effectively target and activate T cells, and can deliver the expression CAR-containing vector into T cells, thereby effectively activating T cells and enhancing the target killing ability of T cells.

To provide retroviral and lentiviral vectors.SOLUTION: The invention provides a retroviral or lentiviral vector having a viral envelope comprising: (i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T cell activating transmembrane protein comprising a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T cell activating transmembrane protein is not part of the viral envelope glycoprotein. When cells such as natural killer cells are transduced with such viral vectors, they are simultaneously activated by the mitogenic T cell activating transmembrane protein and / or the cytokine-based T cell activating transmembrane protein.SELECTED DRAWING: None

Provided is a pseudotyped viral particle, a viral envelope surface thereof comprising immune cell-targeting molecules and / or immune cell-activating molecules. Corresponding targeting molecules are designed on the basis of cell receptors to be targeted, enabling targeting of different types of cells. The application scope is broad, including but not limited to the rapid preparation of CAR-T, CAR-NK, and other immunotherapeutic cells in vitro without the need for sorting and activation, as well as the direct generation of CAR-T, CAR-NK, and other immunotherapeutic cells in vivo.

Crimean-Congo hemorrhagic fever virus (CCHFV) is an important human pathogen. Limited evidence suggests that antibodies can protect humans against lethal CCHFV disease, but the protective efficacy of antibodies has never been evaluated in adult animal models. Here adult mice were used to investigate the protection provided by glycoprotein-targeting neutralizing and non-neutralizing monoclonal antibodies (mAbs) against CCHFV infection. A single non-neutralizing antibody (mAb-13G8) was identified that protected adult type I interferon deficient mice >90% when treatment was initiated prior to virus exposure and >60% when administered after virus exposure. Neutralizing antibodies known to protect neonatal mice from lethal CCHFV infection, failed to confer protection regardless of IgG subclass. The target of mAb-13G8 was identified as GP38, one of multiple proteolytically-cleaved glycoproteins derived from the CCHFV glycoprotein precursor polyprotein. Robust protection required complement activity, but not Fc-receptor functionality. Consistently, it was found that GP38 previously identified as a secreted molecule also localizes to viral envelope and cellular plasma membranes. This study reveals GP38 as an important antibody target for CCHFV and lays the foundation to develop novel vaccines and immunotherapeutic against CCHFV in human.

The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same.

The invention is suitable for the technical field of veterinary drugs, and provides a preparation aiming at porcine reproductive and respiratory syndrome and African swine fever and a preparation method thereof. The preparation is prepared from the following raw materials: a modified polydatin inclusion compound, a nano radix astragali-herba houttuyniae compound, medium-chain fatty glyceride, organic acid sustained-release microcapsules, fermented ammonium glycyrrhizinate, selenized radix isatidis polysaccharide, modified quercetin, modified mannitol and a medicinal carrier. According to the preparation for the porcine reproductive and respiratory syndrome and the African swine fever, the modified polydatin inclusion compound and the modified quercetin are added, the bioavailability is improved through modification, and virus replicase is directly inhibited; the medium-chain fatty glyceride destroys a lipid layer of a virus envelope and blocks virus invasion; the organic acid sustained-release microcapsules are continuously released in the intestinal tract, so that the pH is reduced to inhibit the virus activity, and meanwhile, the intestinal flora is regulated; after the nanometer astragalus membranaceus-houttuynia cordata compound is subjected to enzymolysis nanocrystallization, the immunostimulatory activity of astragalus polysaccharide and houttuynia cordata flavone is improved, and phagocytosis of macrophages and secretion of interferon are promoted.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

The present invention relates to the application of snake venom polypeptide Hc-CATH in the preparation of drugs for preventing and treating Zika virus infection. The present invention takes the cathelicidin family antimicrobial peptide Hc-CATH derived from the venom gland of blue ring sea snake as the research object, and intends to clarify the role and molecular mechanism of Hc-CATH in ZIKV infection. The research of the present invention found that Hc-CATH can significantly inhibit the infection of ZIKV in vitro and in vivo, and has both preventive and therapeutic effects. The results show that Hc-CATH can directly act on ZIKV, destroy the viral envelope, induce the leakage of the viral genome, and thus inactivate viral particles; Hc-CATH can also reduce the protein level of the host cell viral receptor AXL, reducing the susceptibility of host cells to Zika virus. Combined with the small molecular weight and simple structure of the antimicrobial peptide Hc-CATH, it has broad development and application prospects.

The present disclosure provides enveloped delivery vehicles (EDVs) comprising a nucleic acid-binding effector polypeptide, or a nucleic acid encoding the nucleic acid-binding effector polypeptide, where the EDV comprises a fusion polypeptide comprising (i) a viral envelope protein and (ii) a targeting polypeptide that provides for binding to a target cell. The present disclosure provides methods of using an EDV of the present disclosure for delivery of, e.g., a nucleic acid-binding effector polypeptide, to a eukaryotic cell.

Angiotensin-converting enzyme 2(ACE2) has been confirmed as a specific receptor for several β group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

This invention belongs to the field of veterinary biological agent technology, specifically relating to a bacterial-enzyme complex preparation for the prevention and treatment of transmissible gastroenteritis (TGEV) in pigs, its preparation method, and its application. The bacterial-enzyme complex preparation comprises microcapsule particles; the core material of each microcapsule particle includes a complex of probiotics and a synergistic enzyme system; the complex of probiotics includes *Lactobacillus rhamnosus*, *Bacillus coagulans*, *Pediococcus pentosus*, and *Kluyveromyces marsupialis*. In the bacterial-enzyme complex preparation for the prevention and treatment of TGEV provided by this invention, the complex probiotics and the synergistic enzyme system form a synergistic effect. Lactic acid secreted by *Lactobacillus rhamnosus* can lower the intestinal pH, disrupting the TGEV survival environment; antimicrobial peptides produced by *Bacillus coagulans* can directly cleave the viral capsid protein; lysozyme can degrade viral envelope polysaccharides; and neutral protease, β-glucanase, and xylanase can destroy the viral adsorption sites on the intestinal mucosa. This quadruple action significantly enhances the antiviral effect.

The invention relates to a lentiviral vector or retroviral vector and application thereof in infection of B cells, establishment of acquired immunity in subjects and preparation of broad-spectrum neutralizing antibodies. A virus envelope of the lentiviral vector or the retroviral vector contains a targeting molecule targeting B cells and carries a broad-spectrum neutralizing antibody gene; the viral glycoprotein of the lentiviral vector or retroviral vector may further comprise a first mutation that attenuates its ability to bind to a receptor and a second mutation that enhances its ability to antagonize complement inactivation, the capacity of the lentiviral vector or the retroviral vector for targeted transduction of B cells in a subject and preparation of broad-spectrum neutralizing antibodies is further enhanced.

The present application provides novel viral envelope glycoproteins for viral vector pseudotyping, novel designs for synthetic antigen receptors (SARs), novel signal chains for constructing SAR, novel antigen binding domains, and novel methods for generating SAR expressing cells. These novel methods and compositions have broad applications in cell therapy.

Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.

The current disclosure includes a modular vaccine platform. Also included are monkeypox vaccines that protect against pathogenic monkeypox (Mpox) species, as well as their variants. The vaccines typically include a modified mRNA encoding at least one immunogen, such as a viral envelope protein, cell surface binding protein, or a biologically effective / significant fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions that can be used to generate an immune response to pathogens, including monkeypox virus, in a subject.

A pharmaceutical composition with dual anti-inflammatory and antiviral activity against COVID-19 and related respiratory pathogens, the composition comprising the following: (a) Curcumin in an amount of 1.5 to 5.0% by weight, which acts as a primary anti-inflammatory agent, suppressing cyclooxygenase-2 (COX-2) expression and interleukin-6 (IL-6) signaling; b) Quercetin in an amount of 2.0 to 6.0 wt%, which acts as an antiviral flavonoid and is able to inhibit SARS-CoV-2 proteases (3CLpro and PLpro) and the penetration of the virus; (c) Zinc oxide nanoparticles (ZnO-NPs) in an amount of 0.5 to 2.0 wt%, with an average particle size between 20 and 40 nm, which facilitate the destruction of viral envelope proteins and increase cellular zinc uptake; d) Ascorbic acid (vitamin C) in an amount of 1.0 to 4.0 wt.%, which acts as an antioxidant to neutralize reactive oxygen species (ROS) produced during viral infections and inflammatory reactions; (e) Glycyrrhizin, extracted from licorice glabra, in an amount of 1.0 to 3.0% by weight, acts as an immunomodulator, stabilizes cytokine levels and reduces pneumonia; and (f) a pharmaceutically acceptable carrier medium consisting of liposomal, polymeric or PEG-based excipients in an amount of 80 to 90 wt.%, which ensures sustained release and improved bioavailability of the active substances.